Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorene SCHEMBL545861 | 0.80 | MAOA (0.68) | MAOACES1BCHECHRM2HTR1A | |
| Fluorene SCHEMBL31388525 | 0.80 | MAOA (0.68) | MAOACES1BCHECHRM2HTR1A | |
| Fluorene SCHEMBL29355380 | 0.80 | MAOA (0.68) | MAOACES1BCHECHRM2HTR1A | |
| Fluorene SCHEMBL29478468 | 0.80 | MAOA (0.68) | MAOACES1BCHECHRM2HTR1A | |
| Fluorene SCHEMBL8180 | 0.80 | MAOA (0.68) | MAOACES1BCHECHRM2HTR1A | |
| SCHEMBL17901678 | 0.78 | ALOX15 (0.47) | MAOACES1BCHECHRM2HTR1A | |
| SCHEMBL2626979 | 0.78 | CYP3A4 (0.46) | MAOACES1BCHECHRM2HTR1A | |
| SCHEMBL732656 | 0.78 | MAOA (0.73) | MAOACES1BCHEALDH1A1KDM4E | |
| Fluorene SCHEMBL6739194 | 0.78 | MAOA (0.65) | MAOACES1BCHECHRM2HTR1A | |
| Fluorene SCHEMBL10626727 | 0.78 | MAOA (0.65) | MAOACES1BCHECHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | disclosed |
| EP-2722042-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2019-05-29 | — | — | EP | disclosed |
| US-9890133-B2 | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2018-02-13 | — | — | US | disclosed |
| US-20160297789-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-10-13 | — | — | US | disclosed |
| US-9464067-B2 | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2016-10-11 | — | — | US | disclosed |
| EP-2722042-A2 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | Korea Research Institute of Chemical Technology (KR) | 2014-04-23 | — | — | EP | disclosed |
| US-7705174-B2 | Condensed polycyclic π-conjugated organic material, intermediate product therefor, and method of manufacturing condensed polycyclic π-conjugated organic material | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20060100433-A1 | n-conjugated organic material of polycyclic fused ring type,intermediate therefor, and process for producing n-conjugated organic material of polycyclic fused ring type | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1548019-A1 | -CONJUGATED ORGANIC MATERIAL OF POLYCYCLIC FUSED RING TYPE, INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING-CONJUGATED ORGANIC MATERIAL OF POLYCYCLIC FUSED RING TYPE | Japan Science and Technology Agency (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297789-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | RNASE1, IAPP, TESK1 | MAOA 365/4885CES1 3357/4885BCHE 2114/4885 |
| US-20060100433-A1 | n-conjugated organic material of polycyclic fused ring type,intermediate therefor, and process for producing n-conjugated organic material of polycyclic fused ring type | SLC39A11, NQO1, SLC43A1 | MAOA 2420/4885CES1 3073/4885BCHE 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.